What we do
Recent reports from the World Health Organization (WHO) and the Lancet Commission on Malaria Eradication have made clear that defeating malaria will demand new tools, including new and better medicines. The 2019 WHO World Malaria Report states that global malaria deaths are declining at a slower rate than in recent years and highlights the need for improved interventions to treat the most vulnerable populations, including babies. The PAMAfrica consortium was created to take up this challenge and implements a flexible portfolio approach to the development of new antimalarials and thus achieving SDG 3 “Ensure healthy lives and promote well-being for all at all ages”. It brings together scientific expertise from nine African and European partners.
The consortium will conduct three clinical trials, supporting efforts to build clinical capacity and train scientists across Africa. The projects will include development of the first new malaria treatment for babies under 5kg, a new fast-acting medicine for the treatment of severe malaria, and a new combination to treat drug-resistant uncomplicated malaria.